Myopia Control: a Comparison Study Between Atropine and MiSight

Description

This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.

Conditions

Myopia

Study Overview

Study Details

Study overview

This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.

Myopia Control in the Pediatric Population: a Comparison of MiSight, Naturalvue Multifocal, and Atropine 0.05%

Myopia Control: a Comparison Study Between Atropine and MiSight

Condition
Myopia
Intervention / Treatment

-

Contacts and Locations

Chicago

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Children age of 5-12 years old at their baseline exam
  • * Children with a spherical equivalent refractive error of +0.50D (minimal hyperopia) to -7.50 D (high myopia)
  • * Gestational age ≥ 32 weeks.
  • * Birth weight \>1500g.
  • * Current or previous form of myopia control
  • * Current or previous use of bifocal, progressive- addition lenses, or multifocal contact lenses
  • * Known atropine allergy or contact lens intolerance (allergy to only one can still allow enrollment in the other group)
  • * Abnormality of cornea, lens, central retina, iris, or ciliary body
  • * Current or prior history of manifest strabismus, amblyopia, or nystagmus
  • * Current or previous myopia treatment with atropine, pirenzepine or another anti-muscarinic agent.
  • * Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses.
  • * Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression.
  • * Abnormality of the cornea, lens, central retina, iris, or ciliary body.
  • * Prior eyelid, strabismus, intraocular, or refractive surgery.
  • * Down syndrome or cerebral palsy.
  • * Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease)
  • * Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence refractive development
  • * Any condition that in the judgement of the investigator could potentially influence refractive development.
  • * Existing conditions that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, diabetes mellitus, pre-diabetes)
  • * Inability to comprehend and/or perform any study-related clinical tests

Ages Eligible for Study

5 Years to 12 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ann & Robert H Lurie Children's Hospital of Chicago,

Magdalena Stec, OD, PRINCIPAL_INVESTIGATOR, Ann & Robert H Lurie Children's Hospital of Chicago

Study Record Dates

2026-03-13